Use of Intravesical Chemotherapy in the US Following Publication of a Randomized Clinical Trial

Patrick Lewicki; Spyridon P Basourakos; Camilo Arenas-Gallo; Yuqing Qiu; Megan Prunty; Douglas S Scherr; Jonathan E Shoag

doi:10.1001/jamanetworkopen.2022.0602

Use of Intravesical Chemotherapy in the US Following Publication of a Randomized Clinical Trial

JAMA Netw Open. 2022 Mar 1;5(3):e220602. doi: 10.1001/jamanetworkopen.2022.0602.

Authors

Patrick Lewicki¹, Spyridon P Basourakos¹, Camilo Arenas-Gallo², Yuqing Qiu³, Megan Prunty², Douglas S Scherr¹, Jonathan E Shoag^{1

2}

Affiliations

¹ Department of Urology, NewYork-Presbyterian Hospital, Weill Cornell Medicine, New York, New York.
² Department of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio.
³ Department of Healthcare Policy and Research, Weill Cornell Medicine, New York, New York.

Abstract

This cross-sectional study examines the use of intravesical chemotherapy after transurethral resection of bladder tumor before and after publication of a randomized clinical trial showing the benefits of intravesical chemotherapy.

Publication types

Letter
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Administration, Intravesical
Female
Humans
Male
Urinary Bladder Neoplasms* / drug therapy